Non-Stimulant ADHD Medication: A Patient's Guide to Strattera, Wellbutrin, and Qelbree

Most ADHD conversations start with stimulants. And for good reason: methylphenidate and amphetamine formulations have strong evidence, reach effect within hours, and work for 70 to 80 percent of patients who try them. But the remaining 20 to 30 percent have reasons stimulants are not the right fit: comorbid anxiety that stimulants worsen, a substance use history, cardiovascular concerns, significant insomnia, or intolerable side effects across multiple stimulant trials.

For those patients, three non-stimulant options have meaningful evidence and distinct clinical profiles. Understanding how they differ, what to expect during the adjustment period, and what to track as you start one changes the probability that treatment actually sticks.

When Non-Stimulants Are the Right Starting Point

Stimulants remain first-line for ADHD, but several clinical situations make non-stimulants a better or necessary choice:

• History of substance use disorder or living with someone in recovery (stimulants are Schedule II controlled substances)

• Comorbid anxiety that worsens with stimulant activation

• Significant cardiovascular concerns including elevated blood pressure or heart rate

• Persistent insomnia or appetite suppression that does not resolve with dose timing adjustments

• Previous stimulant trials producing intolerable side effects across multiple formulations

• Patient preference to avoid controlled substances for practical, logistical, or personal reasons

Non-stimulants are not a second-tier option by definition. For the patients they fit, they provide consistent 24-hour coverage, no rebound effects when the dose wears off, and no controlled substance logistics. A 2024 meta-analysis found that both stimulants and non-stimulants improve quality of life in patients with ADHD with moderate effect sizes, with atomoxetine showing a Hedges’ g of 0.30 (95% CI 0.19 to 0.40) compared to placebo.

Strattera (Atomoxetine): The Established Option

Strattera became the first FDA-approved non-stimulant ADHD medication in 2002 and remains the most studied option in this class. Its active ingredient, atomoxetine hydrochloride, is a selective norepinephrine reuptake inhibitor (NRI). It increases available norepinephrine in the prefrontal cortex, the brain region most centrally involved in attention, impulse control, and executive function.

Key facts:

• Approved for: ADHD in children 6 and older, adolescents, and adults

• Mechanism: Selective norepinephrine reuptake inhibition; does not directly affect dopamine

• Onset: Partial improvement within 1 to 2 weeks; full therapeutic effect at 4 to 6 weeks

• Dosing: Once daily or divided into two doses (morning and late afternoon)

• Coverage: 24 hours at steady state

• Generic available: Yes (atomoxetine), substantially lower cost than brand

Common side effects during adjustment include nausea, dry mouth, decreased appetite, fatigue, and possible modest increase in heart rate. Taking with food significantly reduces GI symptoms. Taking it in the morning may reduce sleep disruption for some patients.

Important: Strattera carries an FDA black box warning about increased risk of suicidal thoughts in children and adolescents. Close monitoring during the first several weeks of treatment is required, particularly in younger patients.

Qelbree (Viloxazine ER): The Newer Non-Stimulant

Qelbree (viloxazine extended-release) received FDA approval for ADHD in children and adolescents in April 2021 and for adults in April 2022, making it the first novel non-stimulant ADHD treatment approved in over 20 years.

Viloxazine was originally developed in Europe as an antidepressant. Its repurposing for ADHD reflects a better understanding of its mechanism: in addition to norepinephrine reuptake inhibition, viloxazine has serotonin 5-HT2C agonism and 5-HT2B antagonism, a profile that may contribute to its effects on mood and emotional regulation beyond what norepinephrine reuptake inhibition alone explains.

Key facts:

• Approved for: ADHD in children 6 and older, adolescents, and adults

• Mechanism: Norepinephrine reuptake inhibition plus serotonin 5-HT2C/2B modulation

• Onset: Initial improvements often visible within 1 to 2 weeks; faster than Strattera

• Dosing: Extended-release capsule, once daily; can be opened and sprinkled on soft food

• Coverage: 24 hours with ER formulation

• Generic available: No (brand only, higher cost)

A Phase 3 open-label extension trial found that long-term viloxazine ER was well-tolerated in pediatric patients, with ADHD-RS total scores improving by -24.3 points at month 3 and -26.1 at month 12 from double-blind baseline. Adult data similarly showed continued symptom improvement over extended use.

Common side effects include somnolence, headache, nausea, decreased appetite, fatigue, and in some cases irritability. Most are mild to moderate and improve with time.

Important: Qelbree also carries an FDA black box warning about increased suicidal thoughts in children and adolescents. Close monitoring during early treatment is required.

Wellbutrin (Bupropion): The Off-Label Option

Bupropion (Wellbutrin XL, Wellbutrin SR) is FDA-approved for depression and seasonal affective disorder, not ADHD. Its use for ADHD is off-label, based on its mechanism and consistent clinical use in adult psychiatry. Discuss this explicitly with your prescriber when it is offered for ADHD.

Bupropion works as a norepinephrine-dopamine reuptake inhibitor (NDRI). By blocking reuptake of both dopamine and norepinephrine, it addresses two neurotransmitters associated with ADHD executive function. This dual mechanism distinguishes it from Strattera and Qelbree, which primarily target norepinephrine.

Key facts:

• FDA status for ADHD: Off-label

• Mechanism: Norepinephrine and dopamine reuptake inhibition

• Onset: Mood effects within 1 to 2 weeks; ADHD symptom improvement typically 3 to 4 weeks

• Dosing: Once or twice daily depending on formulation (IR, SR, XL)

• Generic available: Yes, generic bupropion is substantially lower cost

Best fits: adults with both ADHD and depression or seasonal mood patterns, patients who have not responded to dedicated non-stimulants, and those for whom cost is a significant factor.

Important contraindications: bupropion is not appropriate for patients with a seizure history or eating disorders. It can be activating and may worsen anxiety. Do not combine with MAOIs. Liver disease requires dose adjustment.

How to Choose Between Them

No test identifies which non-stimulant will work best for a given patient. Prescribers select based on clinical presentation, comorbidities, patient priorities, and cost considerations.

• Choose Strattera when: you want the most evidence-backed option with established long-term data, generic cost matters, or you need once-daily coverage with the most clinical familiarity.

• Choose Qelbree when: faster onset is important, pediatric data is particularly relevant, or serotonin modulation may be clinically useful (e.g., emotional dysregulation alongside ADHD).

• Choose Wellbutrin when: ADHD co-occurs with depression or seasonal mood patterns, previous dedicated non-stimulants have not worked, or generic cost is a primary driver.

Head-to-head trials comparing these three medications are limited. Effect sizes for viloxazine ER are generally smaller than stimulants but comparable to atomoxetine, suggesting they are approximate clinical equivalents at the population level, with individual response varying.

What to Track When Starting a Non-Stimulant

Non-stimulants require patience that stimulants do not. Patients who stop because the medication “is not working” after two weeks often have not given it adequate time. Knowing what to watch for makes the waiting period clinically useful rather than anxious.

Daily tracking during the first 4 to 6 weeks should capture:

• Core ADHD symptoms: focus, task completion, impulsivity, emotional regulation

• Mood and energy (bupropion in particular can be activating)

• Sleep quality (non-stimulants can cause drowsiness or, in some cases, insomnia)

• Appetite changes

• Side effects: nausea, headache, changes in heart rate, dry mouth

• For children and adolescents: mood changes, irritability, any statements about self-harm (given black box warnings)

This data, collected daily and reviewed by a prescriber, makes dose adjustment decisions faster and more accurate, and reduces the risk of stopping treatment during an uncomfortable adjustment period that would resolve with continued use.

How SiggyMD Approaches Non-Stimulant Management

Non-stimulants require close monitoring during titration precisely because they are slow to show full effect. A patient who experiences nausea in week one and no symptom improvement until week four needs clinical support during that gap, not a follow-up appointment scheduled for week six.

“The biggest risk with non-stimulants is that patients stop before they’ve given the medication enough time,” says Daniel Montville, MD, Psychiatrist, of the SiggyMD clinical team. “The adjustment window is when monitoring matters most. If we can see side effects as they develop and flag them in real time, we can manage them. If we’re waiting for a quarterly appointment, patients often just stop without telling anyone.”

Daily check-ins that capture symptom trajectory, side effect signals, and sleep data create a clinical record that does not require a visit to update. When a patient’s nausea is worsening at week two or their appetite suppression is becoming clinically significant, the care team responds before the patient makes the decision to stop on their own.

What Members Are Saying

AM

A.M., 29

Adult ADHD, Anxiety

“I tried two stimulants and both made my anxiety significantly worse. My prescriber at Siggy suggested Strattera and told me exactly what to expect over the first six weeks. Weeks one and two were hard with nausea, but we adjusted the timing. By week five, I noticed a real difference in my ability to follow through on tasks.”

KS

K.S., 37

Adult ADHD, Depression

“I had untreated ADHD and depression for years and didn’t realize they were related. My Siggy prescriber started me on Wellbutrin because it could address both. It’s been the first treatment that made a difference for both conditions. The fact that someone was watching my check-in data meant the dose got adjusted before I would have ever thought to ask.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Bottom Line

Non-stimulant ADHD medications work differently from stimulants, have no abuse potential, and are the right fit for a meaningful subset of patients. The trade-off is a slower onset that requires monitoring and patience during the adjustment period before full effect arrives.

Strattera has the most established evidence. Qelbree offers faster onset and a slightly different mechanism. Wellbutrin is the off-label option best suited for adults with comorbid depression. What all three share is the need for consistent daily use and clinical support during the weeks before the full effect is felt.

Sources

• Mansour GK, et al. The Viloxazine Paradox: A Noradrenergic Agent’s Journey From Antidepressant Obscurity to ADHD Precision Therapy. CNS Neuroscience & Therapeutics. 2026;32(4):e70839.

• Findling RL, et al. Viloxazine ER Capsules in Children and Adolescents with ADHD: Phase 3 Open-Label Extension Trial. CNS Drugs. 2025;39(11):1157-1172.

• Childress A, et al. Viloxazine ER Capsules for Adult ADHD: Open-Label Extension. CNS Drugs. 2024;38(11):891-907.

• Bellato A, et al. Pharmacological Treatment for ADHD on Quality of Life: Systematic Review and Meta-Analysis. JAACAP. 2024;64(3):346-361.

• Childress A, et al. Viloxazine ER Capsules for Adult ADHD Treatment. Expert Review of Neurotherapeutics. 2023;23(11):945-953.

• National Institute of Mental Health. Attention-Deficit/Hyperactivity Disorder. NIMH. Accessed May 2026.

• U.S. Food and Drug Administration. FDA Drug Safety Information. FDA.gov. Accessed May 2026.

• American Academy of Pediatrics. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD. Pediatrics. 2019;144(4):e20192528.